Business Context and Reporting Period
This is a Transition Report (Form 10-Q) for Celsion Corporation (Note: Metadata listed "Imunon, Inc." but the filing text identifies the registrant as Celsion Corporation) for the period from October 1, 2003, to December 31, 2003. The company is a clinical-stage biotechnology firm focused on thermotherapy systems for cancer and benign prostatic hyperplasia (BPH). The filing notes a change in fiscal year-end from September 30 to December 31, effective December 31, 2003.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2003 | Three Months Ended Dec 31, 2002 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,953,834) | $(1,934,821) |
| Operating Expenses | $2,966,763 | $1,937,472 |
| Cash Flow from Operations | $(2,758,888) | $(1,880,919) |
| Cash and Cash Equivalents (Ending) | $12,272,407 | $1,050,606 |
| Working Capital | $12,581,998 | N/A (Fiscal year end differed) |
| Accumulated Deficit | $(60,232,217) | N/A |
| Long-Term Debt | $0 | $0 |
Material Changes vs. Prior Period
- Operating Loss Increase: The loss from operations increased by 53% to $2.97 million, driven primarily by a 92% increase in Research and Development (R&D) expenses to $2.11 million.
- R&D Drivers: The R&D increase was attributed to stock-based compensation, salaries, recruiting/relocation for new employees, and business development costs for BPH, liposome, and gene therapy.
- Liquidity Improvement: Cash balances increased significantly from $1.05 million in the prior year period to $12.27 million, resulting from a private placement offering and warrant exercises.
- Interest Income: Interest income rose 606% to $18,720 due to higher average cash balances.
Guidance, Outlook, and Risks
- Outlook: Management expects to expend approximately $10 million in the fiscal year ending December 31, 2004, for clinical testing and overhead. They anticipate current cash resources will fund operations through December 31, 2004.
- Revenue Expectations: No product revenues are expected until regulatory approvals are obtained. Potential revenue generation is contingent on the approval of the BPH 800 system during fiscal 2004.
- Capital Needs: The company has no committed sources of additional financing beyond current resources. Future funding will likely require equity or debt financing, strategic alliances, or other sources.
- Risks: Key risks include the inability to raise additional capital, delays in clinical trials, failure to obtain regulatory approvals, and potential breach of licensing agreements if funding for required trials is not secured.
- Recent Financing: On December 12, 2003, the company completed a private placement raising gross proceeds of $4.0 million (4.55 million shares and warrants). Boston Scientific holds a significant stake and has agreed to invest an additional $10 million upon meeting certain milestones.
Investor Verification Checklist
- Verify the status of clinical trials for the BPH 800 system and breast cancer treatment systems.
- Confirm the timeline and probability of regulatory approval for the BPH 800 system in fiscal 2004.
- Assess the sufficiency of the $12.3 million cash balance against the projected $10 million expenditure for the upcoming fiscal year.
- Review the terms of the agreement with Boston Scientific regarding the $10 million milestone-based investment.
- Monitor the company's ability to secure additional financing if product sales do not materialize as anticipated.